Welcome to our dedicated page for Hca Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCA Healthcare’s sheer scale—hundreds of hospitals, thousands of beds, and billions in Medicare reimbursements—means its SEC disclosures overflow with complex details about payer mix, same-facility admissions, malpractice reserves, and regulatory audits. Finding the one line on outpatient surgery margins or the note on cyber breaches can feel impossible.
Stock Titan rescues your schedule. Our AI digests every HCA Healthcare annual report 10-K simplified, flags shifts in reimbursement rates inside the HCA Healthcare quarterly earnings report 10-Q filing, and delivers HCA Healthcare Form 4 insider transactions real-time alerts the second they hit EDGAR. Curious about sudden executive sales? The platform highlights HCA Healthcare executive stock transactions Form 4. Need context on a facility divestiture? We attach plain-English notes to the latest HCA Healthcare 8-K material events explained. Our AI-powered summaries translate technical accounting into clear language—ideal for understanding HCA Healthcare SEC documents with AI rather than wading through footnotes.
Investors use these insights to monitor reimbursement exposure, benchmark occupancy trends, and compare segment margins quarter over quarter. Whether you’re researching HCA Healthcare proxy statement executive compensation before a vote or seeking an HCA Healthcare earnings report filing analysis to project free cash flow, every document is indexed, searchable, and updated in real time. That includes the must-track HCA Healthcare insider trading Form 4 transactions for pattern analysis. Complex filings, clarified—so you can act before the market does.
Dow Inc. (DOW) Q2-25 10-Q highlights (3 mos. ended 6/30/25):
- Sales: $10.1 bn, -7% YoY (Q2-24 $10.9 bn).
- Net loss: $(801) mm vs profit $458 mm prior year; loss per share $(1.18) vs $0.62.
- Main driver: $591 mm restructuring & asset-related charges (none LY).
- Operating cash flow: $(366) mm YTD vs +$1.3 bn LY; working-capital outflow led by $935 mm receivables build.
- Six-month data: Sales $20.5 bn (-5%), net loss $(1.1) bn vs profit $996 mm; EPS $(1.62) vs $1.35.
- Balance sheet (6/30/25 vs 12/31/24): Cash $2.4 bn (+10%), LT debt $16.2 bn (+3%), equity $18.6 bn (+4%); retained earnings fell $2.1 bn, offset by $1.5 bn APIC increase from sale of Diamond Infrastructure Solutions stake and $2.4 bn proceeds to NCI.
- Capex: $1.35 bn YTD (-6% YoY); quarterly dividend unchanged at $0.70 (1.40 YTD).
The sharp swing to loss stems largely from restructuring, weaker volumes/pricing and higher interest expense. Negative operating cash flow and modest debt uptick pressure liquidity, though cash balance and equity rose on divestiture proceeds. Management cites macro, energy and raw-material volatility and ongoing restructuring as key risk factors.
Cantaloupe, Inc. (NASDAQ: CTLP) has agreed to be acquired by 365 Retail Markets, LLC in an all-cash transaction valued at $11.20 per common share. The deal will be executed through a merger of Catalyst MergerSub Inc. into Cantaloupe, after which Cantaloupe will become a wholly owned subsidiary of Catalyst Holdco II, Inc. Preferred shareholders will be cashed out immediately prior to closing at $11.00 per share plus accrued dividends. The Board of Directors unanimously approved the Agreement and Plan of Merger signed 15 June 2025 and recommends that shareholders vote “FOR� the Merger Proposal, the Advisory Compensation Proposal, and any needed Adjournment Proposal at a still-to-be-scheduled virtual special meeting.
Key terms include:
- Consideration: $11.20 cash per outstanding common share (treasury, rollover and certain other shares excluded).
- Total funding need: approximately $945 million, to cover equity payouts, preferred redemption, option/RSU settlements, debt pay-off and fees. 365 has secured committed debt financing to meet these obligations.
- Conditions: majority shareholder approval (common and preferred voting together on an as-converted basis) and expiration or termination of the Hart-Scott-Rodino waiting period. The merger is not subject to a financing condition.
- Termination fee: Cantaloupe must pay 365 $31.5 million under specified circumstances, including acceptance of a superior proposal.
- Fairness opinion: J.P. Morgan rendered a written opinion on 15 June 2025 that the $11.20 cash consideration is fair, from a financial point of view, to unaffiliated common shareholders.
- Delisting: Upon completion, CTLP shares will be removed from Nasdaq and deregistered with the SEC.
Directors and certain shareholders (including Hudson Executive Capital LP) have entered into voting agreements covering an undisclosed percentage of voting power. All equity awards held by employees and directors will vest or be cashed out as described in the proxy. The merger is expected to close in the second half of 2025, subject to the satisfaction of closing conditions.
HCA Healthcare has filed a Form S-8 to register an additional 13,150,000 shares of common stock ($0.01 par value) under its 2020 Stock Incentive Plan for Key Employees. This amendment to the plan became effective April 24, 2025.
Key details of the filing:
- Registration is for additional shares authorized under the amended 2020 Stock Plan
- Company is classified as a large accelerated filer
- Filing incorporates by reference multiple documents including the 2024 Annual Report, Q1 2025 Quarterly Report, and recent Current Reports
The filing includes executive signatures from key leadership including Samuel N. Hazen (CEO), Michael A. Marks (CFO), and Thomas F. Frist III (Chairman). This stock plan registration indicates HCA Healthcare's continued investment in employee compensation and retention through equity-based incentives.
FAQ
What is the current stock price of Hca Healthcare (HCA)?
What is the market cap of Hca Healthcare (HCA)?
What is HCA Healthcare Inc?
How does HCA generate revenue?
What types of services does HCA Healthcare provide?
How is HCA Healthcare positioned within the industry?
What differentiates HCA from its competitors?
In which regions does HCA operate?
What challenges does HCA face in the healthcare market?
How does HCA ensure quality in its medical services?
